Search

Your search keyword '"Delforge, Michel"' showing total 1,139 results
Start Over Author "Delforge, Michel"
1,139 results on '"Delforge, Michel"'

201. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival

Author

de Witte, Theo, Brand, Ronald, van Biezen, Anja, Mufti, Ghulam, Ruutu, Tapani, Finke, Jürgen, von dem Borne, Peter, Vitek, Antonin, Delforge, Michel, Alessandrino, Paolo, Harlahakis, Nicolas, Russell, Nigel, Martino, Roberto, Verdonck, Leo, Kröger, Nicholas, and Niederwieser, Dietger

Published
2009
Full Text
View/download PDF

204. Insights on multiple myeloma treatment strategies

Author

Mateos, Mara-Victoria Ludwig, Heinz Bazarbachi, Ali Beksac, Meral Bladé, Joan Boccadoro, Mario Cavo, Michele Delforge, Michel Dimopoulos, Meletios A Facon, Thierry others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2019

209. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

Author

Ossenkoppele, Gert J., Graveland, Wilfried J., Sonneveld, Pieter, Daenen, Simon M.G.J., Biesma, Douwe H., Verdonck, Leo F., Schaafsma, M. Ron, Westveer, Petra H.M., Peters, Godefridus J., Noordhuis, Paul, Muus, Petra, Selleslag, Dominik, van der Holt, Bronnie, Delforge, Michel, Löwenberg, Bob, and Verhoef, Gregor E.G.

Published
2004
Full Text
View/download PDF

210. 220 - Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant

Author

Agha, Mounzer, Dhakal, Binod, Dytfeld, Dominik, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M, Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., and Mateos, Maria-Victoria

Published
2022
Full Text
View/download PDF

211. 73 - Updated Results of Cartitude-2: Ciltacabtagene Autoleucel (cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor T Cell (CAR-T) Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma (MM) after 1–3 Prior Lines of Therapy

Author

Hillengass, Jens, Cohen, Adam D., Delforge, Michel, Cohen, Yael C, Goldschmidt, Hartmut, Weisel, Katja Christina, Raab, Marc-Steffen, Scheid, Christoph, Schecter, Jordan M, De Braganca, Kevin C., Varsos, Helen, Yeh, Tzu-Min, Wang, Liwei, Vogel, Martin, Corsale, Christina, Akram, Muhammad, Pacaud, Lida, Nesheiwat, Tonia, Agha, Mounzer, and Einsele, Hermann

Published
2022
Full Text
View/download PDF

212. 61 - Safety and Efficacy of Ciltacabtagene Autoleucel (cilta-cel), a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: Results from Cartitude-2

Author

Cohen, Adam D., Delforge, Michel, Agha, Mounzer, van de Donk, Niels W.C.J., Cohen, Yael C, Hillengass, Jens, Anguille, Sébastien, Kerre, Tessa, Roeloffzen, Wilfried, Schecter, Jordan M, De Braganca, Kevin C., Varsos, Helen, Wang, Liwei, Vogel, Martin, Zudaire, Enrique, Corsale, Christina, Akram, Muhammad, Geng, Dong, Nesheiwat, Tonia, Pacaud, Lida, Sonneveld, Pieter, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

215. Phase 2b results of the STORM study: oral selinexor plus low dose dexamethasone (SD) in patients with penta-refractory myeloma (Penta-MM)

Author

Jagannath, Sundar Vogl, Dan T. Dimopoulos, Meletios-Athanasios and Nooka, Ajay Huff, Carol Moreau, Philippe Cole, Craig and Richter, Josh Dingli, David Vij, Ravi Tuchman, Sascha and Raab, Marc-Steffen Weisel, Katja Delforge, Michel and Kaminetzky, David Cornell, Robert Frank Stewart, A. Keith and Hoffman, James Godby, Kelly N. Parker, Terri Lynn Levy, Moshe Schreder, Martin Meuleman, Nathalie Frenzel, Laurent and Mohty, Mohmad Choquet, Sylvain Yee, Andrew and Gavriatopoulou, Maria Costa, Luciano Shah, Jatin and Picklesimer, Carla Saint-Martin, Jean-Richard Li, Lingling and Kauffman, Michael Shacham, Sharon Richardson, Paul Chari, Ajai

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2018

219. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Author

Moreau, Philippe, primary, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, Cook, Gordon, additional, Mateos, Ma Victoria, additional, Nahi, Hareth, additional, Goldschmidt, Hartmut, additional, Dimopoulos, Meletios A., additional, Lucio, Paulo, additional, Bladé, Joan, additional, Delforge, Michel, additional, Hajek, Roman, additional, Ludwig, Heinz, additional, Facon, Thierry, additional, Miguel, Jesus F. San, additional, and Einsele, Hermann, additional

Published
2019
Full Text
View/download PDF

220. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Author

Chari, Ajai, primary, Vogl, Dan T., additional, Gavriatopoulou, Maria, additional, Nooka, Ajay K., additional, Yee, Andrew J., additional, Huff, Carol A., additional, Moreau, Philippe, additional, Dingli, David, additional, Cole, Craig, additional, Lonial, Sagar, additional, Dimopoulos, Meletios, additional, Stewart, A. Keith, additional, Richter, Joshua, additional, Vij, Ravi, additional, Tuchman, Sascha, additional, Raab, Marc S., additional, Weisel, Katja C., additional, Delforge, Michel, additional, Cornell, Robert F., additional, Kaminetzky, David, additional, Hoffman, James E., additional, Costa, Luciano J., additional, Parker, Terri L., additional, Levy, Moshe, additional, Schreder, Martin, additional, Meuleman, Nathalie, additional, Frenzel, Laurent, additional, Mohty, Mohamad, additional, Choquet, Sylvain, additional, Schiller, Gary, additional, Comenzo, Raymond L., additional, Engelhardt, Monika, additional, Illmer, Thomas, additional, Vlummens, Philip, additional, Doyen, Chantal, additional, Facon, Thierry, additional, Karlin, Lionel, additional, Perrot, Aurore, additional, Podar, Klaus, additional, Kauffman, Michael G., additional, Shacham, Sharon, additional, Li, Lingling, additional, Tang, Shijie, additional, Picklesimer, Carla, additional, Saint-Martin, Jean-Richard, additional, Crochiere, Marsha, additional, Chang, Hua, additional, Parekh, Samir, additional, Landesman, Yosef, additional, Shah, Jatin, additional, Richardson, Paul G., additional, and Jagannath, Sundar, additional

Published
2019
Full Text
View/download PDF

223. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Author

Moreau, Philippe, primary, Attal, Michel, additional, Hulin, Cyrille, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Benboubker, Lotfi, additional, Béné, Marie C, additional, Broijl, Annemiek, additional, Caillon, Hélène, additional, Caillot, Denis, additional, Corre, Jill, additional, Delforge, Michel, additional, Dejoie, Thomas, additional, Doyen, Chantal, additional, Facon, Thierry, additional, Sonntag, Cécile, additional, Fontan, Jean, additional, Garderet, Laurent, additional, Jie, Kon-Siong, additional, Karlin, Lionel, additional, Kuhnowski, Frédérique, additional, Lambert, Jérôme, additional, Leleu, Xavier, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Mathiot, Claire, additional, Orsini-Piocelle, Frédérique, additional, Perrot, Aurore, additional, Stoppa, Anne-Marie, additional, van de Donk, Niels WCJ, additional, Wuilleme, Soraya, additional, Zweegman, Sonja, additional, Kolb, Brigitte, additional, Touzeau, Cyrille, additional, Roussel, Murielle, additional, Tiab, Mourad, additional, Marolleau, Jean-Pierre, additional, Meuleman, Nathalie, additional, Vekemans, Marie-Christiane, additional, Westerman, Matthijs, additional, Klein, Saskia K, additional, Levin, Mark-David, additional, Fermand, Jean Paul, additional, Escoffre-Barbe, Martine, additional, Eveillard, Jean-Richard, additional, Garidi, Reda, additional, Ahmadi, Tahamtan, additional, Zhuang, Sen, additional, Chiu, Christopher, additional, Pei, Lixia, additional, de Boer, Carla, additional, Smith, Elena, additional, Deraedt, William, additional, Kampfenkel, Tobias, additional, Schecter, Jordan, additional, Vermeulen, Jessica, additional, Avet-Loiseau, Hervé, additional, and Sonneveld, Pieter, additional

Published
2019
Full Text
View/download PDF

224. Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.

Author

Perrot, Aurore, primary, Facon, Thierry, additional, Plesner, Torben, additional, Usmani, Saad Zafar, additional, Kumar, Shaji, additional, Bahlis, Nizar J., additional, Ramasamy, Karthik, additional, Roussel, Murielle, additional, Araujo, Carla, additional, Jaccard, Arnaud, additional, Delforge, Michel, additional, McKay, Caroline, additional, Gries, Katharine, additional, Trudeau, Jeremiah, additional, Hulin, Cyrille, additional, and Weisel, Katja, additional

Published
2019
Full Text
View/download PDF

225. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

Author

Sonneveld, Pieter, primary, Broijl, Annemiek, additional, Gay, Francesca, additional, Boccadoro, Mario, additional, Einsele, Hermann, additional, Blade, Joan, additional, Dimopoulos, Meletios A., additional, Delforge, Michel, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Schjesvold, Fredrik, additional, Lonergan, Sarah, additional, Smith, Elena, additional, Carson, Robin L., additional, Crist, Wendy, additional, Garvin, Wendy S., additional, Vermeulen, Jessica, additional, and Moreau, Philippe, additional

Published
2019
Full Text
View/download PDF

226. Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study.

Author

Durie, Brian G., primary, Goldschmidt, Hartmut, additional, Mateos, Maria-Victoria, additional, Gonzalez, Veronica, additional, Du, Juan, additional, Kim, Kihyun, additional, Merlini, Giampaolo, additional, Mangiacavalli, Silvia, additional, Min, Chang Ki, additional, Dimopoulos, Meletios A., additional, Kastritis, Efstathios, additional, Ludwig, Heinz, additional, Esteves, Graca, additional, Handa, Hiroshi, additional, Escalante, Fernando, additional, Fernández de Larrea Rodríguez, Carlos, additional, Delforge, Michel, additional, Cameron, Chris, additional, Rajkumar, S. Vincent, additional, and Kumar, Shaji, additional

Published
2019
Full Text
View/download PDF

228. Insights on Multiple Myeloma Treatment Strategies

Author

Mateos, María-Victoria, primary, Ludwig, Heinz, additional, Bazarbachi, Ali, additional, Beksac, Meral, additional, Bladé, Joan, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Delforge, Michel, additional, Dimopoulos, Meletios A., additional, Facon, Thierry, additional, Geraldes, Catarina, additional, Goldschmidt, Hartmut, additional, Hájek, Roman, additional, Hansson, Markus, additional, Jamroziak, Krzysztof, additional, Leiba, Merav, additional, Masszi, Tamás, additional, Mendeleeva, Larisa, additional, O’Dwyer, Michael, additional, Plesner, Torben, additional, San-Miguel, Jesús F., additional, Straka, Christian, additional, van de Donk, Niels W.C.J., additional, Yong, Kwee, additional, Zver, Samo, additional, Moreau, Philippe, additional, and Sonneveld, Pieter, additional

Published
2019
Full Text
View/download PDF

230. Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice

Author

Hulin, Cyrille, primary, de la Rubia, Javier, additional, Dimopoulos, Meletios A., additional, Terpos, Evangelos, additional, Katodritou, Eirini, additional, Hungria, Vania, additional, De Samblanx, Hadewijch, additional, Stoppa, Anne‐Marie, additional, Aagesen, Jesper, additional, Sargin, Deniz, additional, Sioni, Anastasia, additional, Belch, Andrew, additional, Diels, Joris, additional, Olie, Robert A., additional, Robinson, Don, additional, Potamianou, Anna, additional, van de Velde, Helgi, additional, and Delforge, Michel, additional

Published
2018
Full Text
View/download PDF

231. Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Author

Chari, Ajai, primary, Vogl, Dan T., additional, Dimopoulos, Meletios A, additional, Nooka, Ajay K, additional, Huff, Carol Ann, additional, Moreau, Philippe, additional, Cole, Craig E., additional, Richter, Joshua, additional, Dingli, David, additional, Vij, Ravi, additional, Tuchman, Sascha A, additional, Raab, Marc S, additional, Weisel, Katja, additional, Delforge, Michel, additional, Kaminetzky, David, additional, Cornell, Robert Frank, additional, Stewart, A Keith, additional, Hoffman, James, additional, Godby, Kelly N., additional, Parker, Terri L, additional, Levy, Moshe, additional, Schreder, Martin, additional, Meuleman, Nathalie, additional, Frenzel, Laurent, additional, Mohty, Mohamad, additional, Sylvain, Choquet, additional, Yee, Andrew J., additional, Gavriatopoulou, Maria, additional, Costa, Luciano J, additional, Shah, Jatin J., additional, Picklesimer, Carla, additional, Saint-Martin, Jean-Richard, additional, Li, Lingling, additional, Kauffman, Michael G., additional, Shacham, Sharon, additional, Richardson, Paul, additional, and Jagannath, Sundar, additional

Published
2018
Full Text
View/download PDF

233. Cognitive Impairment, Hypoalbuminemia, High CRP Level and Past History of Gastro-Intestinal Ulcer: 4 Markers of Frailty Which Identify Older Patients with Malignant Hemopathies Who Shouldn't Benefit from Chemotherapy

Author

Dubruille, Stephanie, primary, Kenis, Cindy, additional, Thibaud, Vincent, additional, Libert, Yves, additional, Delforge, Michel, additional, Dal Lago, Lissandra, additional, Roos, Myriam, additional, Borghgraef, Cindy, additional, Thierry, Pepersack, additional, Wildiers, Hans, additional, and Bron, Dominique, additional

Published
2018
Full Text
View/download PDF

239. P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE‐CEL) VERSUS STANDARD REGIMENS.

Author

Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa Mckiver, Mihaela, Cook, Mark, and Rodríguez‐Otero, Paula

Published
2023
Full Text
View/download PDF

240. P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL‐LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2‐YEAR FOLLOW‐UP.

Author

Moreau, Philippe, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Lindsey‐Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Vincent, Laure, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels W.C.J., Ocio, Enrique, In‘t Groen‐Damen, Ester, Roccia, Tito, Schecter, Jordan, Haddad, Imene, Strulev, Vadim, and Mitchell, Lada

Published
2023
Full Text
View/download PDF

243. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

Author

Weisel, Katja, Mateos, Maria-Victoria, Gay, Francesca, Delforge, Michel, Cook, Gordon, Szabo, Zsolt, Desgraz, Renaud, DeCosta, Lucy, and Moreau, Philippe

Abstract

To understand the profile of best responders (complete response or better [≥CR]) to carfilzomib, we described the characteristics, progression-free survival (PFS), overall survival (OS) data, and the safety of patients who achieved ≥CR to carfilzomib-based treatment in ASPIRE and ENDEAVOR. In post hoc analyses from ASPIRE and ENDEAVOR, median PFS and OS were longer for ≥CR patients versus those who achieved a very good partial response or partial response (VGPR/PR). In the carfilzomib arm of ASPIRE, median PFS was 50.4 months for ≥CR versus 22.1 months for VGPR/PR; median OS was 67.0 versus 44.2 months, respectively. In the carfilzomib arm of ENDEAVOR, median PFS was 34.0 for ≥CR versus 20.4 months for VGPR/PR; median OS was non-estimable. Despite the longer treatment duration, fewer patients with ≥CR versus VGPR/PR experienced treatment-emergent adverse events that led to discontinuation of carfilzomib-based treatment in ASPIRE or ENDEAVOR. Low serum lactate dehydrogenase was the only factor associated with achieving ≥CR vs patients not achieving CR in ASPIRE in multivariate regression analyses. No association was found between cytogenetic risk status and reaching ≥CR. Carfilzomib treatment may lead to rapid and deep responses, irrespective of most patient characteristics.

Published
2021
Full Text
View/download PDF

244. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Author

San Miguel, Jesús F., Weisel, Katja C., Song, Kevin W., Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrián, Martínez-López, Joaquín, Chen, Chritine, Renner, Christoph, Bahlis, Nizar Jacques, Yu, Xin, Teasdale, Terri, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H., Dimopoulos, Meletios A., UAM. Departamento de Medicina, Instituto de Investigación del Hospital de La Princesa (IP), San Miguel, Jesus F, Weisel, Katja C, Song, Kevin W, Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Renner, Christoph, Bahlis, Nizar Jacque, Yu, Xin, Teasdale, Terri, Sternas, Lar, Jacques, Christian, Zaki, Mohamed H, and Dimopoulos, Meletios A

Subjects
Oncology, Male, medicine.medical_specialty, MM-003, Medicina, Pharmacology, Dexamethasone, Recurrence, Multiple myeloma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival analysis, Lenalidomide, Aged, Aged, 80 and over, Bortezomib, business.industry, MM, Pomalidomide, pomalidomide + low-dose dexamethasone, high-dose dexamethasone, Hematology, Articles, Pomalidomide, medicine.disease, Survival Analysis, Thalidomide, Treatment, Treatment Outcome, Tolerability, Retreatment, Female, business, Multiple Myeloma, medicine.drug, Follow-Up Studies
Abstract

Pomalidomide is a distinct oral IMiD immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in 455 patients with refractory or relapsed and refractory multiple myeloma after failure of bortezomib and lenalidomide treatment. Initial results demonstrated significantly longer progression-free survival and overall survival with an acceptable tolerability profile for pomalidomide + low-dose dexamethasone vs high-dose dexamethasone. This secondary analysis describes patient outcomes by treatment history and depth of response. Pomalidomide + low-dose dexamethasone significantly prolonged progression-free survival and favored overall survival vs high-dose dexamethasone for all subgroups analyzed, regardless of prior treatments or refractory status. Both univariate and multivariate analyses showed that no variable relating to either the number (≤ or > 3) or type of prior treatment was a significant predictor of progression-free survival or overall survival. No cross-resistance with prior lenalidomide or thalidomide treatment was observed. Patients achieving a minimal response or better to pomalidomide + low-dose dexamethasone treatment experienced a survival benefit, which was even higher in those achieving at least a partial response (17.2 and 19.9 months, respectively, as compared with 7.5 months for patients with less than minimal response). These data suggest that pomalidomide + low-dose dexamethasone should be considered a standard of care in patients with refractory or relapsed and refractory multiple myeloma regardless of prior treatment. ClinicalTrials.gov: NCT01311687; EudraCT: 2010-019820-30. ispartof: Haematologica vol:100 issue:10 pages:1334-9 ispartof: location:Italy status: published

Published
2015

245. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Author

Terpos, Evangelos, primary, Katodritou, Eirini, additional, de la Rubia, Javier, additional, Hungria, Vania, additional, Hulin, Cyrille, additional, Roussou, Maria, additional, Delforge, Michel, additional, Bries, Greet, additional, Stoppa, Anne-Marie, additional, Aagesen, Jesper, additional, Sargin, Deniz, additional, Belch, Andrew, additional, Ahlberg, Lucia, additional, Diels, Joris, additional, Olie, Robert A., additional, Robinson, Don, additional, Spencer, Mike, additional, Potamianou, Anna, additional, van de Velde, Helgi, additional, and Dimopoulos, Meletios A., additional

Published
2018
Full Text
View/download PDF

246. Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)

Author

Jagannath, Sundar, primary, Vogl, Dan T., additional, Dimopoulos, Meletios-Athanasios, additional, Nooka, Ajay, additional, Huff, Carol, additional, Moreau, Philippe, additional, Cole, Craig, additional, Richter, Josh, additional, Dingli, David, additional, Vij, Ravi, additional, Tuchman, Sascha, additional, Raab, Marc-Steffen, additional, Weisel, Katja, additional, Delforge, Michel, additional, Kaminetzky, David, additional, Cornell, Robert Frank, additional, Stewart, A. Keith, additional, Hoffman, James, additional, Godby, Kelly N., additional, Parker, Terri Lynn, additional, Levy, Moshe, additional, Schreder, Martin, additional, Meuleman, Nathalie, additional, Frenzel, Laurent, additional, Mohty, Mohmad, additional, Choquet, Sylvain, additional, Yee, Andrew, additional, Gavriatopoulou, Maria, additional, Costa, Luciano, additional, Shah, Jatin, additional, Picklesimer, Carla, additional, Saint-Martin, Jean-Richard, additional, Li, Lingling, additional, Kauffman, Michael, additional, Shacham, Sharon, additional, Richardson, Paul, additional, and Chari, Ajai, additional

Published
2018
Full Text
View/download PDF

247. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when

Author

Caers, Jo, primary, Garderet, Laurent, additional, Kortüm, K. Martin, additional, O’Dwyer, Michael E., additional, van de Donk, Niels W.C.J., additional, Binder, Mascha, additional, Dold, Sandra Maria, additional, Gay, Francesca, additional, Corre, Jill, additional, Beguin, Yves, additional, Ludwig, Heinz, additional, Larocca, Alessandra, additional, Driessen, Christoph, additional, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Gramatzki, Martin, additional, Zweegman, Sonja, additional, Einsele, Hermann, additional, Cavo, Michele, additional, Goldschmidt, Hartmut, additional, Sonneveld, Pieter, additional, Delforge, Michel, additional, Auner, Holger W., additional, Terpos, Evangelos, additional, and Engelhardt, Monika, additional

Published
2018
Full Text
View/download PDF

248. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Author

Jurczyszyn, Artur, primary, Castillo, Jorge J., additional, Avivi, Irit, additional, Czepiel, Jacek, additional, Davila, Julio, additional, Vij, Ravi, additional, Fiala, Mark A., additional, Gozzetti, Alessandro, additional, Grząśko, Norbert, additional, Milunovic, Vibor, additional, Hus, Iwona, additional, Mądry, Krzysztof, additional, Waszczuk-Gajda, Anna, additional, Usnarska-Zubkiewicz, Lidia, additional, Dębski, Jakub, additional, Atilla, Erden, additional, Beksac, Meral, additional, Mele, Giuseppe, additional, Sawicki, Waldemar, additional, Jayabalan, David, additional, Charliński, Grzegorz, additional, Gyula Szabo, Agoston, additional, Hajek, Roman, additional, Delforge, Michel, additional, Kopacz, Agnieszka, additional, Fantl, Dorotea, additional, Waage, Anders, additional, Crusoe, Edvan, additional, Hungria, Vania, additional, Richardson, Paul, additional, Laubach, Jacob, additional, Guerrero-Garcia, Thomas, additional, Liu, Jieqi, additional, and Vesole, David H., additional

Published
2018
Full Text
View/download PDF

250. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, primary, Delforge, Michel, additional, Facon, Thierry, additional, Einsele, Hermann, additional, Gay, Francesca, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Boccadoro, Mario, additional, Hajek, Roman, additional, Mohty, Mohamad, additional, Cavo, Michele, additional, Dimopoulos, Meletios A, additional, San-Miguel, Jesús F, additional, Terpos, Evangelos, additional, Zweegman, Sonja, additional, Garderet, Laurent, additional, Mateos, María-Victoria, additional, Cook, Gordon, additional, Leleu, Xavier, additional, Goldschmidt, Hartmut, additional, Jackson, Graham, additional, Kaiser, Martin, additional, Weisel, Katja, additional, van de Donk, Niels W. C. J., additional, Waage, Anders, additional, Beksac, Meral, additional, Mellqvist, Ulf H., additional, Engelhardt, Monika, additional, Caers, Jo, additional, Driessen, Christoph, additional, Bladé, Joan, additional, and Sonneveld, Pieter, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results